GraftAssureDx™ Submitted for FDA Review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Should l Buy IMDX?
Source: Newsfilter
- FDA Review Progress: GraftAssureDx™ was submitted for FDA review on March 25, marking the first-ever dd-cfDNA assay submission, representing a significant milestone after 12 years of clinical development, which is expected to enhance the company's leadership in the kidney transplant market.
- Market Expansion Signals: The number of engaged transplant centers in the U.S. has doubled to 37 in the past three months, covering over 25% of annual transplants, indicating strong market demand for GraftAssureDx™ and suggesting significant future commercialization potential.
- Financing Support: The company completed a $26 million financing in February, aimed at supporting expansion into the heart transplantation market while also commercializing kidney testing, which is expected to accelerate product launch and enhance revenue streams.
- Clinical Data Advantage: Independent studies have shown GraftAssure technology's superior performance in transplant rejection testing, boosting clinician confidence in switching to in-house testing, thereby laying a solid foundation for future market promotion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMDX
Wall Street analysts forecast IMDX stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 3.440
Low
8.00
Averages
8.50
High
9.00
Current: 3.440
Low
8.00
Averages
8.50
High
9.00
About IMDX
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insight Molecular Diagnostics Q4 2025 Earnings Call Highlights
- FDA Submission Milestone: Insight Molecular Diagnostics has submitted GraftAssureDx to the FDA, marking a significant advancement in the dd-cfDNA testing space, which is expected to accelerate product commercialization and enhance market competitiveness.
- Clinical Engagement Growth: Since the fall, 28 transplant centers have initiated the registry process, bringing the company closer to its goal of 50 centers, indicating strong market demand and effective clinical outreach strategies.
- Capital Raise and Spending Management: CFO Andrea James reported the completion of a $26 million capital raise, with maintenance spending projected at $5.5 million per quarter and growth spending at $2 million, ensuring financial stability while expanding market access.
- Market Outlook and Challenges: The company anticipates low lab services revenue in 2026, necessitating successful commercialization for self-sustainability; despite strong demand for heart transplant testing, clinician adoption remains a significant hurdle.
See More
Insight Molecular Diagnostics Q4 Earnings Analysis
- Earnings Performance: Insight Molecular Diagnostics Inc. reported a Q4 non-GAAP EPS of -$0.27, missing expectations by $0.03, indicating ongoing pressure on profitability that could undermine investor confidence.
- Revenue Decline: The company's Q4 revenue of $1.14 million represents a 23.5% year-over-year decline, although it exceeded market expectations by $0.86 million, it still reflects challenges in the business that may impact future liquidity.
- Financing Activity: Insight Molecular Diagnostics announced a $26 million registered direct offering, which aims to strengthen its capital structure, yet the decline in share price suggests market concerns regarding the company's outlook.
- Market Reaction: According to Seeking Alpha's Quant Rating, Insight Molecular Diagnostics' stock has performed poorly, potentially prompting investors to reassess their investment strategies in the biotechnology sector.
See More
GraftAssureDx™ Submitted for FDA Review
- FDA Review Progress: GraftAssureDx™ was submitted for FDA review on March 25, marking the first-ever dd-cfDNA assay submission, representing a significant milestone after 12 years of clinical development, which is expected to enhance the company's leadership in the kidney transplant market.
- Market Expansion Signals: The number of engaged transplant centers in the U.S. has doubled to 37 in the past three months, covering over 25% of annual transplants, indicating strong market demand for GraftAssureDx™ and suggesting significant future commercialization potential.
- Financing Support: The company completed a $26 million financing in February, aimed at supporting expansion into the heart transplantation market while also commercializing kidney testing, which is expected to accelerate product launch and enhance revenue streams.
- Clinical Data Advantage: Independent studies have shown GraftAssure technology's superior performance in transplant rejection testing, boosting clinician confidence in switching to in-house testing, thereby laying a solid foundation for future market promotion.
See More
INSIGHT MOLECULAR DIAGNOSTICS INC - ANNOUNCES Q4 2025 NET LOSS OF $23.0 MILLION, EQUIVALENT TO $0.72 PER SHARE
Financial Performance: The company reported a net loss of $23.0 million for the fourth quarter of 2025.
Earnings Per Share: The loss translates to $0.72 per share for the reported period.
See More
Insight Molecular Diagnostics Set to Announce Q4 Earnings on March 26
- Earnings Announcement Schedule: Insight Molecular Diagnostics Inc. is set to announce its Q4 earnings on March 26 after market close, with consensus EPS estimate at -$0.24 and revenue expected at $0.28M, reflecting an 81.2% year-over-year decline, which could negatively impact the company's financial outlook.
- Historical Performance Review: Over the past year, IMDX has beaten EPS estimates 50% of the time, while only achieving a 25% success rate in beating revenue estimates, indicating challenges in profitability and revenue growth.
- Financing Dynamics: Insight Molecular Diagnostics recently completed a $26 million registered direct offering, which, while aimed at enhancing liquidity, has led to a decline in share price, reflecting market concerns about the company's future prospects.
- Market Rating Analysis: According to Seeking Alpha's Quant Rating, Insight Molecular Diagnostics is under scrutiny, and investors should closely monitor the upcoming earnings report to assess the company's future investment value.
See More
Insight Molecular Achieves Key Milestones for GraftAssureDx
- Clinical Trial Progress: Insight Molecular Diagnostics completed a three-site reproducibility study for the GraftAssureDx™ test kit at Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health, collecting sufficient clinical samples to support FDA submission, marking a significant advancement in organ health testing.
- ISO Certification Achieved: The company received ISO 13485 certification on February 26, which not only paves the way for regulatory submissions in the U.K. and EU but also reduces risks during the FDA review process, enhancing quality assurance for future manufacturing and commercialization.
- Significant Market Potential: iMDx plans to launch an industry-leading molecular diagnostic test kit in 2026, expected to deliver new value in the over $2 billion organ rejection testing market, further strengthening the company's position in this sector.
- Accelerated Internal Performance Studies: The company is rapidly completing internal analytical performance studies, with approximately 340 instrument and assay cycles remaining, ensuring robust data support for the FDA submission while effectively coordinating between clinical trials and internal research.
See More
Insight Molecular Diagnostics Q4 2025 Earnings Call Highlights
- FDA Submission Milestone: Insight Molecular Diagnostics has submitted GraftAssureDx to the FDA, marking a significant advancement in the dd-cfDNA testing space, which is expected to accelerate product commercialization and enhance market competitiveness.
- Clinical Engagement Growth: Since the fall, 28 transplant centers have initiated the registry process, bringing the company closer to its goal of 50 centers, indicating strong market demand and effective clinical outreach strategies.
- Capital Raise and Spending Management: CFO Andrea James reported the completion of a $26 million capital raise, with maintenance spending projected at $5.5 million per quarter and growth spending at $2 million, ensuring financial stability while expanding market access.
- Market Outlook and Challenges: The company anticipates low lab services revenue in 2026, necessitating successful commercialization for self-sustainability; despite strong demand for heart transplant testing, clinician adoption remains a significant hurdle.
See More
Insight Molecular Diagnostics Q4 Earnings Analysis
- Earnings Performance: Insight Molecular Diagnostics Inc. reported a Q4 non-GAAP EPS of -$0.27, missing expectations by $0.03, indicating ongoing pressure on profitability that could undermine investor confidence.
- Revenue Decline: The company's Q4 revenue of $1.14 million represents a 23.5% year-over-year decline, although it exceeded market expectations by $0.86 million, it still reflects challenges in the business that may impact future liquidity.
- Financing Activity: Insight Molecular Diagnostics announced a $26 million registered direct offering, which aims to strengthen its capital structure, yet the decline in share price suggests market concerns regarding the company's outlook.
- Market Reaction: According to Seeking Alpha's Quant Rating, Insight Molecular Diagnostics' stock has performed poorly, potentially prompting investors to reassess their investment strategies in the biotechnology sector.
See More
GraftAssureDx™ Submitted for FDA Review
- FDA Review Progress: GraftAssureDx™ was submitted for FDA review on March 25, marking the first-ever dd-cfDNA assay submission, representing a significant milestone after 12 years of clinical development, which is expected to enhance the company's leadership in the kidney transplant market.
- Market Expansion Signals: The number of engaged transplant centers in the U.S. has doubled to 37 in the past three months, covering over 25% of annual transplants, indicating strong market demand for GraftAssureDx™ and suggesting significant future commercialization potential.
- Financing Support: The company completed a $26 million financing in February, aimed at supporting expansion into the heart transplantation market while also commercializing kidney testing, which is expected to accelerate product launch and enhance revenue streams.
- Clinical Data Advantage: Independent studies have shown GraftAssure technology's superior performance in transplant rejection testing, boosting clinician confidence in switching to in-house testing, thereby laying a solid foundation for future market promotion.
See More
INSIGHT MOLECULAR DIAGNOSTICS INC - ANNOUNCES Q4 2025 NET LOSS OF $23.0 MILLION, EQUIVALENT TO $0.72 PER SHARE
Financial Performance: The company reported a net loss of $23.0 million for the fourth quarter of 2025.
Earnings Per Share: The loss translates to $0.72 per share for the reported period.
See More
Insight Molecular Diagnostics Set to Announce Q4 Earnings on March 26
- Earnings Announcement Schedule: Insight Molecular Diagnostics Inc. is set to announce its Q4 earnings on March 26 after market close, with consensus EPS estimate at -$0.24 and revenue expected at $0.28M, reflecting an 81.2% year-over-year decline, which could negatively impact the company's financial outlook.
- Historical Performance Review: Over the past year, IMDX has beaten EPS estimates 50% of the time, while only achieving a 25% success rate in beating revenue estimates, indicating challenges in profitability and revenue growth.
- Financing Dynamics: Insight Molecular Diagnostics recently completed a $26 million registered direct offering, which, while aimed at enhancing liquidity, has led to a decline in share price, reflecting market concerns about the company's future prospects.
- Market Rating Analysis: According to Seeking Alpha's Quant Rating, Insight Molecular Diagnostics is under scrutiny, and investors should closely monitor the upcoming earnings report to assess the company's future investment value.
See More
Insight Molecular Achieves Key Milestones for GraftAssureDx
- Clinical Trial Progress: Insight Molecular Diagnostics completed a three-site reproducibility study for the GraftAssureDx™ test kit at Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health, collecting sufficient clinical samples to support FDA submission, marking a significant advancement in organ health testing.
- ISO Certification Achieved: The company received ISO 13485 certification on February 26, which not only paves the way for regulatory submissions in the U.K. and EU but also reduces risks during the FDA review process, enhancing quality assurance for future manufacturing and commercialization.
- Significant Market Potential: iMDx plans to launch an industry-leading molecular diagnostic test kit in 2026, expected to deliver new value in the over $2 billion organ rejection testing market, further strengthening the company's position in this sector.
- Accelerated Internal Performance Studies: The company is rapidly completing internal analytical performance studies, with approximately 340 instrument and assay cycles remaining, ensuring robust data support for the FDA submission while effectively coordinating between clinical trials and internal research.
See More
